Tomonori Yano

Dr. Tomonori Yano

MD, PhD

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2019 in Digestive Endoscopy
Verified
Journal Article
Closed access
PDF file
HWHao Wu
Hao Wu
TMTatsunori Minamide
Tatsunori Minamide
Tomonori YanoTomonori Yano
Tomonori Yano

4 September 2008 in Endoscopy
Verified
Journal Article
Closed access
PDF file
Tomonori YanoTomonori Yano
Tomonori Yano
MMM. Muto
M. Muto
SHS. Hattori
S. Hattori
KMK. Minashi
K. Minashi
MOM. Onozawa
M. Onozawa
SYS. Yoshida
S. Yoshida
Background and study aims: Local failure after definitive chemoradiotherapy (CRT) in patients with esophageal cancer remains one of the major problems in finding a cure. Endoscopic mucosal resection (EMR) is one treatment option when failure lesions are superficial. However, there are no relevant long-term survival data. The aim of this study was to clarify the long-term survival of salvage EMR. Patients and methods: Between January 1998 and March 2004, 289 patients with esophageal squamous cell carcinoma were treated with definitive CRT at the National Cancer Center Hospital East, Japan. Of these 289 patients, 21 patients with local failure without lymph-node or distant metastases were treated with salvage EMR. The technique of salvage EMR involved a strip biopsy method. We retrospectively analyzed the long-term survival data for the patients who underwent salvage EMR. Results: At a median follow-up period of 54 months (range, 16 – 108 months), eight of 21 patients (38 %) were alive with no recurrence and two patients had died from another disease but with no recurrence of esophageal cancer. Local recurrence after EMR was detected in four patients, with local and lymph-node recurrence in two patients, and lymph-node and/or distant metastases in five patients. The 5-year survival rate from the initiation of salvage EMR was 49.1 %. There were no severe complications associated with EMR. Conclusion: EMR is one of the curative salvage treatment options for local failure after definitive CRT, if the failure lesion is superficial and there are no lymph-node or distant metastases.

25 October 2011 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
Tomonori YanoTomonori Yano
Tomonori Yano
MMManabu Muto
Manabu Muto
KMKeiko Minashi
Keiko Minashi
JIJunko Iwasaki
Junko Iwasaki
TKTakashi Kojima
Takashi Kojima
AOAtsushi Ohtsu
Atsushi Ohtsu
Local failure at the primary site is a major problem after chemoradiotherapy (CRT) in patients with esophageal squamous cell carcinoma (ESCC). Salvage surgery is the only treatment option with curative intent, but it is associated with high morbidity and mortality. The aim of this study was to evaluate the efficacy and safety of salvage photodynamic therapy (PDT) after CRT. Patients with histologically proven local failure limited to the submucosal layer, and without any metastasis after definitive CRT (≥50 Gy) for ESCC were enrolled in the study. PDT began with intravenous administration of 2 mg/kg of porfimer sodium followed 48–72 hr later by excimer dye laser irradiation with a fluence of 75 J/cm2. The primary endpoint was a complete response (CR) to treatment with PDT, and the secondary endpoints were toxicity related to PDT, progression‐free survival (PFS) and overall survival (OS). Twenty‐five patients were enrolled in the study. A CR was attained in 19 of 25 patients treated with PDT (CR rate, 76%; 95% CI, 55–91%). One treatment‐related death (4%) caused by gastrointestinal hemorrhage at the irradiated site occurred 33 days after PDT. No adverse events greater than grade 3 were related to PDT in the other patients. After a median follow‐up of 48 months after PDT, the PFS and OS at 3 years were 40% (95% CI, 21–59%) and 38% (95% CI, 17–60%), respectively. PDT is a potentially curative and tolerable salvage treatment after CRT for carefully selected patients with local failure without any metastasis.

23 July 2012 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
Tomonori YanoTomonori Yano
Tomonori Yano
MMManabu Muto
Manabu Muto
KYKenichi Yoshimura
Kenichi Yoshimura
MNMiyuki Niimi
Miyuki Niimi
YEYasumasa Ezoe
Yasumasa Ezoe
HIHiroyasu Iishi
Hiroyasu Iishi
Background: Photodynamic therapy (PDT) is a less invasive and effective salvage treatment for local failure after chemoradiotherapy (CRT) for esophageal cancer, however it causes a high rate of skin phototoxicity and requires a long sun shade period. Talaporfin sodium is a rapidly cleared photosensitizer that is expected to have less phototoxicity. This study was undertaken to clarify the optimum laser fluence rate of PDT using talaporfin sodium and a diode laser for patients with local failure after CRT or radiotherapy (RT) for esophageal cancer. Methods: This phase I, laser dose escalation study used a fixed dose (40 mg/m2) of intravenous talaporfin sodium administered 4 to 6 hours before irradiation in patients with local failure limited to T2 after CRT or RT (≥ 50 Gy). The primary endpoint was to assess the dose limiting toxicity (DLT) of PDT, and the secondary endpoints were to evaluate the adverse events and toxicity related to PDT. The starting fluence of the 664 nm diode laser was 50 J/cm2, with an escalation plan to 75 J/cm2 and 100 J/cm2. Results: 9 patients with local failure after CRT or RT for ESCC were enrolled and treated in groups of 3 individuals to the third fluence level. No DLT was observed at any fluence level. Phototoxicity was not observed, but one subject had grade 1 fever, three had grade 1 esophageal pain, and 1 had grade 1 dysphagia. Five of 9 patients (55.6%) achieved a complete response after PDT. Conclusions: PDT using talaporfin sodium and a diode laser was safe for local failure after RT in patients with esophageal cancer. The recommended fluence for the following phase II study is 100 J/cm2.

30 December 2019 in Photochemistry and Photobiology
Verified
Journal Article
Closed access
PDF file
Tomonori YanoTomonori Yano
Tomonori Yano
KWKenneth K. Wang
Kenneth K. Wang

4 May 2019 in Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
KNKeiichiro Nakajo
Keiichiro Nakajo
SASeiichiro Abe
Seiichiro Abe
IOIchiro Oda
Ichiro Oda
RIRyu Ishihara
Ryu Ishihara
MTMasaki Tanaka
Masaki Tanaka
Tomonori YanoTomonori Yano
Tomonori Yano